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Abstract
Bariatric surgery may alter the absorption, distribution, metabolism and/or elimination 
(disposition) of orally administered drugs via changes to the gastrointestinal tract anatomy, body 
weight, and adipose tissue composition. As some patients who have undergone bariatric surgery 
will need therapeutic anticoagulation for various indications, appropriate knowledge is needed 
regarding anticoagulant drug disposition and resulting efficacy and safety in this population. We 
review general considerations about oral drug disposition in patients after bariatric surgery, as well 
as existing literature on oral anticoagulation after bariatric surgery. Overall, available evidence on 
therapeutic anticoagulation is very limited and individual drug studies are necessary to learn how 
to safely and effectively use the direct oral anticoagulants. Given the sparsity of presently available 
data, it appears most prudent to use warfarin with INR monitoring, and not direct oral 
anticoagulants, when full-dose anticoagulation is needed after bariatric surgery.
INTRODUCTION
As the prevalence of extreme obesity, defined as a body mass index (BMI) of greater than or 
equal to 40 kg/m2, continues to rise worldwide, so, too, does the number of bariatric 
procedures performed: in the United States alone, an estimated 200,000 bariatric surgeries 
are performed annually 1, 2. Clinicians therefore must make management decisions on 
people who have undergone bariatric surgeries. One such decision is managing therapeutic 
anticoagulation, because inappropriate anticoagulant drug levels can have serious 
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consequences: thromboembolism if levels are too low, or bleeding if levels are too high. In 
the absence of dedicated studies of oral anticoagulation use after bariatric surgery, clinicians 
must consider how bariatric surgery affects the absorption and pharmacokinetics of, and 
hence the efficacy and safety of, oral anticoagulant agents. Herein, we review the available 
literature on how bariatric surgery affects the disposition of oral anticoagulant agents, and 
discuss considerations for managing patients who have had bariatric surgery and need 
therapeutic anticoagulation.
TYPES OF BARIATRIC SURGERY
The term “bariatric surgery” comprises multiple procedures, including adjustable gastric 
banding (AGB), sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and 
biliopancreatic diversion with duodenal switch (BPD-DS) (Figures 1a–d). As of 2014, sleeve 
gastrectomy was the most common bariatric procedure performed in the United States 
(51.7%), followed by RYGB (26.8%), revisions (11%), and gastric banding (9.5%) 3. 
Bariatric surgeries result in weight loss through 1) restriction of caloric intake by reducing 
the volume of the stomach, 2) malabsorption by reducing the effective intestinal surface 
area, or 3) a combination of restriction and malabsorption. SG and AGB are solely 
restrictive. In SG, a longitudinal resection of the stomach reduces its volume to 
approximately 60–80 mL, thereby restricting caloric intake 4, 5. In AGB, an adjustable 
silicone band is placed around the stomach to create a smaller pouch that similarly restricts 
caloric intake. RYGB and BPD-DS use a combination of restriction and malabsorption. 
These surgeries differ in the location and connection of the alimentary channel, the 
biliopancreatic channel, and the common limb. In RYGB, the stomach is stapled to form a 
15–30 mL proximal gastric pouch, which is then connected to an alimentary limb of jejunum 
75–150 cm distally, resulting in a modest degree of malabsorption1. In BPD-DS, the gastric 
volume is reduced to a lesser degree, and the gastric pouch is reattached more distally to the 
terminal ileum 6, which results in a much shorter common channel, a considerable reduction 
in the absorptive surface, and more significant malabsorption.
INFLUENCE OF ANATOMIC CHANGES ON DRUG DISPOSITION
The anatomic changes from bariatric procedures have several physiologic effects on drug 
absorption and resultant bioavailability, which depend on both physiochemical properties of 
the drug (i.e., solubility, degree of ionization, stability, and molecular size) 7 and properties 
of the gastrointestinal tract (pH, blood flow, intestinal transit time, and surface area for 
absorption) 6, 8.
Reduced Caloric Intake
First, the restrictive nature of the procedures leads to reduced caloric intake, which may 
impact drugs that require food to increase bioavailability (Table 1). Therapeutic doses of 
rivaroxaban (15 mg and 20 mg), for example, depend on food to increase absorption:9 the 
area under the curve (AUC) and peak concentration (Cmax) of a 20 mg tablet of rivaroxaban 
increased by 39% and 76%, respectively, with co-administration of food,10 and the 
bioavailability of the 15 mg dose of rivaroxaban reached ≥80% when given with food 11. 
Thus, the absorption of therapeutic rivaroxaban may be reduced in patients placed on very 
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restrictive diets, which can limit caloric intake to as little as 500 kcal daily after bariatric 
surgery. However, the bioavailability of apixaban, dabigatan, edoxaban, and warfarin do not 
appear to be significantly affected by co-administration of food.
Decreased Absorptive Surface
The change in absorptive surface may alter the absorption of drugs as well. The reduced 
volume for gastric acid secretion leads to a more alkaline pH in the gastric pouch, which 
could affect pH-dependent drug dissolution and resultant absorption, particularly of drugs 
that are coated or in controlled-release formulation 12. Dabigatran, for example, requires an 
acidic environment for absorption and, therefore, is packaged in capsules containing tartaric 
acid 13, 14. While an approximately 20% reduction in absorption was seen when dabigatran 
was given with antacids, this is thought not to be clinically meaningful 15. The PK of 
rivaroxaban, apixaban, and edoxaban are not altered by drugs that increase gastric 
pH 10, 16, 17.
Surgical changes that alter the anatomy of the gastrointestinal tract may affect location of 
drug absorption, and in the absence of dedicated studies, indirect evidence such as the 
location of drug absorption (Figure 2) can be used to attempt to predict how oral 
anticoagulant therapy will be affected by bariatric surgery. Apixaban is absorbed primarily 
in the proximal small intestine, with some gastric absorption and limited colonic 
absorption 18–20. Rivaroxaban appears to be absorbed primarily in the stomach, as there is 
reduced absorption (29% decrease in AUC and 56% decrease in Cmax) when the drug is 
released into the proximal small intestine, with further reduction as the drug is released more 
distally into the small intestine and colon 9. Dabigatran is thought to be absorbed in the 
lower stomach and duodenum because of the rapid time to peak levels 21. Moreover, a case 
report showed reduced absorption in short bowel syndrome contributing to insufficient 
anticoagulation and drug levels below published values of therapeutic doses of dabigatran22. 
Edoxaban is predominately absorbed in the proximal small intestine 23. While no apparent 
direct studies of the location of warfarin absorption exist, it is thought to be absorbed 
extensively in the stomach and proximal small intestine according to several case series 24. 
In one report, patients had prolonged prothrombin times after jejunal and ileal bowel 
resection; 25 in others, patients with severe short bowel syndrome were are able to 
adequately absorb warfarin (presumably because stomach and duodenum are intact); and in 
another, a patient who underwent total gastrectomy and RYGB subsequently required much 
higher doses of warfarin to achieve therapeutic levels 26. One patient who had both stomach 
and duodenum removed, however, developed warfarin resistance 24. These case reports 
demonstrate that even with large GI resections, warfarin may still be well absorbed because 
of its high bioavailability, but that it may be difficult to achieve adequate absorption in cases 
with very significant resections that result in the loss of the majority of stomach and 
proximal small intestine. In summary, with the limitations of knowledge highlighted above, 
absorption of the anticoagulants appears to occur in the approximate areas outlined in Figure 
2.
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Other Influences
Anatomic changes that result from bariatric surgery may have additional effects on drug 
disposition. Motility and transit time may be increased in RYGB patients 1, and with less 
time for absorption, drugs theoretically may not be fully absorbed 12, 27. Further, enteric 
metabolism and transport proteins that play a role in the intestinal metabolism of and the 
efflux/influx of drugs across the intestinal wall make critical contributions to the 
bioavailability of numerous drugs, and surgeries that bypass the small intestine may alter 
these mechanisms for a particular drug, thereby affecting the drug’s bioavailability 1, 2. The 
direct impact of bariatric surgery on enteric metabolism and transport, however, remains 
unclear.
INFLUENCE OF WEIGHT AND WEIGHT LOSS ON PHARMACOKINETICS
Volume of Distribution
In addition to changes resulting from the anatomic modifications of bariatric surgery, 
alterations in drug PK due to both excess weight and weight loss may also occur. Volume of 
distribution (Vd), the extent to which a drug distributes into tissues, depends largely on lipid 
solubility and other physicochemical properties of the drug 28. As excess weight in obesity is 
comprised of adipose tissue, the Vd for lipid-soluble drugs may be higher in individuals with 
obesity compared to normal-weight individuals, whereas Vd may be minimally different for 
more water-soluble drugs 7. A reduction in total body and adipose tissue weight from 
dramatic weight loss may change drug disposition depending on a drugs lipophilicity and, 
thus, Vd.
Rivaroxaban has been reported to exhibit moderate lipophilicity, as reflected by its logP 
value (octanol/water partition) coefficient of 1.5 and its low-to-moderate affinity to 
peripheral tissues 29. The other DOACs (logP values range from 1.4 to 2.2) and warfarin 
(logP value of 2.7) also exhibit moderate lipophilicity 30. These physicochemical properties, 
coupled with their relatively low Vd in healthy subjects (Table 1) and modest associations 
between increasing body weight and increasing Vd in population pharmacokinetic 
models 31, 32, suggest that these agents likely partition to some degree into tissue 
(presumably adipose tissue), but largely reside within the vascular space. The clinical 
relevance of weight-associated changes in the Vd of these agents, however, remains unclear.
Clearance
Clearance is the principal determinant of steady-state plasma concentrations of a 
continuously-dosed drug. 28 It is typically mediated by the liver and/or kidney, and depends 
on physiological processes including blood flow and the extraction capability for a given 
drug. The effects of obesity on clearance are not well-defined and likely vary by drug. There 
is limited literature on the effects of weight loss on clearance, and whether clearance in 
individuals who have undergone dramatic weight loss is similar to normal-weight 
individuals who have not been previously obese 28. Since the extent of weight loss 
associated changes in drug distribution and clearance likely vary by drug, precisely 
predicting the effect of bariatric procedure-evoked weight loss on the PK of a specific drug 
requires dedicated study.
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Studies on Effect of Weight on PK of DOACs
It has been demonstrated that body weight extremes can alter the pharmacokinetics of 
apixaban, rivaroxaban, dabigatran and edoxaban following administration of fixed doses 33. 
Following a single dose of apixaban in healthy subjects weighing ≤50 kg (low), 65–85 kg 
(normal), and ≥120 kg (high), high body weight had 30% higher clearance and 24% higher 
Vd 34, which translated into a 31% lower Cmax and 23% lower AUC in the high body weight 
group compared to the normal-weight group. In a similar study conducted with rivaroxaban, 
weight ≤50 kg was associated with a 24% higher Cmax and 14% higher AUC compared to 
weight 70–80 kg; however, weight >120 kg was not associated with significantly altered 
rivaroxaban exposure or Vd 35. Weight ≥100 kg is associated with 21% lower dabigatran 
trough (Cmin) concentration compared to patients weighing 50–100 kg 36. Edoxaban 
exposure in patients with very high body weight has not been reported. Therefore, the 
population of patients with obesity who undergo bariatric surgery may have altered drug 
exposure because of extreme weight. Further, given the PK relationships between drug 
exposure and weight, it would be reasonable to hypothesize that weight loss, particularly 
extreme weight loss secondary to bariatric surgery, would decrease the Vd and clearance and 
increase the exposure and antithrombotic effect of these agents. However, the presence, 
magnitude, time-course, and mechanisms mediating these effects remain unknown and will 
require direct investigation.
Summary of Pharmacokinetic Effects
The mechanisms that underlie these processes are complex and have not been shown to be 
predictable when drugs are studied individually. Indeed, a study found that using PK 
parameters within a biopharmaceutical classification system could not alone explain the 
observed variability in bioavailability after bariatric surgery 4. Therefore, the sum of the 
changes imparted by bariatric procedures makes it difficult, if not impossible, to accurately 
predict oral bioavailability – and, consequently, PK, clinical efficacy and safety – for a given 
drug without a dedicated study of that drug 2, 28.
CLINICAL DATA
Information from direct studies of therapeutic oral anticoagulant use after bariatric surgery is 
very limited and comes mostly from retrospective studies of small numbers of patients.
Vitamin K antagonists (warfarin and others)
Literature is most robust for vitamin K antagonists (VKA) compared to other oral 
anticoagulants. One study compared warfarin dosing in 27 patients before and after bariatric 
surgery (82% post- RYGB and 18% post- GB) to a matched control group of 59 patients 
undergoing alternative abdominal surgeries 37. A significant reduction in the median weekly 
dose of warfarin after bariatric surgery was found, ranging from 7.7 mg/week decrease at 
days 8–14 after surgery to a 30 mg/week decrease at days 50–56 (p<0.01), though the 
absolute change in dosing for individual patients varied substantially, ranging from 0 to 40 
mg/week in the three months following surgery. Interestingly, the weekly dose requirement 
returned to and remained at pre-surgery doses 90–180 days post-operatively. The mechanism 
of reduced dose-requirements after surgery, whether by altered absorption due to anatomic 
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changes or lower vitamin K intake, could not be determined from the study alone 38. 
Another retrospective study demonstrated a rise in “warfarin sensitivity” (as defined by INR 
>3 or the need to decrease warfarin dose) within 30 days of bariatric surgery compared to 
30–150 days after surgery; notably, after 30 days post-operatively, there was a trend toward 
increased warfarin dose requirements 39. Additionally, a smaller study of ten patients found 
that the mean weekly dose of warfarin was reduced by 64% from baseline within 21 days 
after bariatric surgery, with dose requirements rising as time passed, reaching up to 90% of 
pre-surgery mean warfarin requirements at 1 year 40. Furthermore, the average time out of 
therapeutic range was much higher in the first week after surgery compared to weeks 2 and 3 
post-operatively, and the average time out of therapeutic range decreased from weeks 4 to 6. 
Another small retrospective study of twelve patients also found a statistically significant 
reduction of warfarin dose by approximately 25% after bariatric surgery, with a median 
weekly warfarin dose of 37.4 mg before surgery compared to median weekly warfarin dose 
of 32.5 mg after surgery 41. Notably, unlike the studies discussed above, this study did not 
find a significant difference between warfarin doses at 1 and 6 months after surgery.
While the mechanism of reduced warfarin requirements after bariatric surgery remains 
unclear, it may be due in part to alterations in vitamin K intake and absorption; caloric 
reduction post-bariatric surgery has resulted in vitamin K deficiencies 42. Additionally, the 
absorption of vitamin K in the proximal intestine occurs after solubilization into micelles by 
bile salts and products of pancreatic lipolysis, 43 and may be affected by anatomic changes 
resulting from bariatric surgery.
Overall, the literature suggests that warfarin dosing is reduced in the immediate post-
operative period (within 3–4 weeks), with a trend towards increased dose requirements as 
patients are further out from surgery. None of the studies looked at PK parameters or drug 
levels, however, so the mechanism underlying the observed changes remains unclear.
Direct Oral Anticoagulants
There is scant literature on the use of direct oral anticoagulants (DOACs) in the post-
bariatric surgery setting. One case reported successful use of rivaroxaban following bariatric 
surgery: the patient started rivaroxaban 20 mg daily 2–3 months after bariatric surgery due to 
widely variable INRs on warfarin. Rivaroxaban anti-Xa levels measured between 3 and 24 
hours after the initial dose of rivaroxaban, and again three hours after the second day’s dose, 
were within published ranges 44.
CLINICAL GUIDANCE
In the absence of PK/PD and clinical data on the efficacy and safety of DOACs after the 
various bariatric procedures, and the lack of widely available tests and clearly defined 
therapeutic ranges for DOACs, it is difficult to justify their use after bariatric surgery. As 
warfarin’s anticoagulant effect can be routinely monitored, this seems to be the preferred 
agent to use in patients after bariatric surgery until more data on DOACs become available. 
Therefore, our approach to management of oral anticoagulation in patients after bariatric 
surgery is as follows:
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1. We recommend using vitamin K antagonists, rather than DOACs, in patients who 
require full-dose anticoagulation after bariatric surgery, as VKAs can be 
monitored with the INR. We recommend against using DOACs, because 
published data describing DOAC absorption, PK/PD and clinical efficacy and 
safety are too sparse, and there is no PK/PD model to predict DOAC drug 
disposition and action in patients after bariatric surgery.
2. If DOACs are used in a patient after bariatric surgery, we suggest checking a 
drug-specific peak and trough level. If the level falls within the expected 
published ranges 45, continuation of the DOAC seems reasonable. However, if 
the drug-specific level is found to be below or above the expected range, we 
suggest changing to a VKA rather than adjusting the dose of the DOAC. As food 
intake and weight may change in the weeks and months after the surgery, repeat 
DOAC drug level testing may be indicated at certain intervals.
CONCLUSION
There is little literature available on the effects of bariatric surgery on therapeutic 
anticoagulation. Drug disposition depends on food volume, pH, transit time, gastrointestinal 
absorptive surface, and location of drug absorption, which may all affect PK and 
bioavailability of an ingested drug. The changes to drug disposition after bariatric surgery 
are not predictable without independent study of individual drugs. The limited clinical 
literature that exists on therapeutic anticoagulation after bariatric surgery relates to warfarin, 
and suggests lower dose requirements within the first month after surgery, with rising 
requirements as time from surgery increases. There is scant literature on DOACs. At present, 
it appears most prudent to use a vitamin K antagonist rather than a DOAC for therapeutic 
oral anticoagulation after bariatric surgery, as the VKAs can be easily monitored and dose-
adjusted.
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ABBREVIATIONS
AUC area under the curve
AGB adjustable gastric banding
Cmax peak concentration
Cmin trough concentration
DOAC Direct oral anticoagulants
DPD-DS biliopancreatic diversion with duodenal switch
INR international normalized ratio
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PK pharmacokinetics
RYGB Roux-en-Y gastric bypass
SG sleeve gastrectomy
Vd volume of distribution
VKA vitamin K antagonist
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Clinical Significance
- changes in pharmacokinetics and bioavailability of an ingested drug after 
bariatric surgery are not predictable without dedicated study of individual 
drugs
- limited literature exists on therapeutic warfarin after bariatric surgery and 
even less on direct oral anticoagulants after bariatric surgery
- in the absence of dedicated studies, we suggest vitamin K antagonist as the 
oral anticoagulant of choice after bariatric surgery given its ability to be 
monitored and dose-adjusted
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Figure 1. 
A–D: Bariatric procedures. A: Roux-en-Y gastric bypass; B: Sleeve gastrectomy; C: Gastric 
banding. D: Biliopancreatic diversion with duodenal switch.
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Figure 2. 
Location of absorption of anticoagulants
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Table 1
Characteristics of oral antithrombotic
Antithrombotic
agent
Location of
absorption
Volume of
distribution*
Biopharmaceutics Classification
System†
Concurrent food intake impact
on drug absorption
Apixaban Primarily proximal
small intestine; some
gastric absorption 18,
19, 46
21L 47
(0.3 L/kg)
BCS Class III (high solubility, low
permeability)
No effect
Take without regard to food
Dabigatran Lower stomach and
duodenum 21
50-70L 48
(0.7-1 L/kg)
BCS Class II (Low Solubility, High
Permeability)
No effect
Take without regard to food
Edoxaban Proximal small
intestine 23
107 L 49
(1.5 L/kg)
BCS Class IV (low solubility, low
permeability)50
+6-22% 51
Take without regard to food
Rivaroxaban Primarily proximal
small intestine; some
gastric absorption 9, 11
50L
(0.7 L/kg)
BCS Class II (Low Solubility, High
Permeability)29
+39% 10, 11
Take 15 and 20 mg dose with
food to improve bioavailability
Warfarin Proximal 25 0.14 L/kg 52
(10 L)
BCS Class II (Low Solubility, High
Permeability) 53
No effect
*
Reported values obtained from the prescribing information (calculated values based on 70 kg patient)
†
BCS class is a FDA classification system that classifies drugs based on their solubility and intestinal permeability 54
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